greeksoup/ stock research

Rapid Micro Biosystems, Inc.: Q4 FY2025 earnings call

What management said about Q4 FY2025, from the documents filed with the SEC on 12 March 2026: press release. Guidance figures: 3 new. The quarter’s numbers.

Key takeaways

  • Fourth-quarter revenue rose 37%: Revenue was $11.3 million against $8.2 million a year earlier. Product revenue accounted for most of the increase. Source
  • Full-year revenue rose 20%: Full-year 2025 revenue was $33.6 million, up from $28.1 million in 2024. Product revenue was the main contributor to the increase. Source
  • Amgen order expanded global rollout: Amgen placed a significant multi-system order in the fourth quarter to expand its global Growth Direct rollout. Source
  • Quarterly gross margin turned negative: Gross margin was negative 3% in the quarter, against positive 12% a year earlier. Adjusted for the write-off, it was 7%. Source
  • Inventory write-off excluded from adjusted margin: The company wrote off unusable inventory and recorded related warranty expense. Adjusted figures exclude these charges. Source
  • Cash near $39 million at year end: Cash, short-term investments and restricted cash were about $39.0 million at December 31, 2025. Source
  • Four strategic priorities named: Management named accelerating Growth Direct placements, expanding gross margin, new product innovation and prudent cash management as strategic priorities. Source

“We closed 2025 with significant momentum, delivering 20% year-over-year revenue growth,”

Robert Spignesi, President and CEO

Guidance

AreaPeriodFigureAgainst last quarter
Total revenue Sourcefull year 2026$37.0 million to $41.0 millionNew
Growth Direct system placements Sourcefull year 202630 to 38New
Gross margin percentage Sourcefull year 2026approximately 20%New

What changed from last quarter

  • New guidance: Full-year 2026 guidance for revenue, placements and gross margin appears in this release. The preliminary release covered 2025 figures only. Source
  • New: A first-quarter 2026 multi-system order from Samsung Biologics is reported. The January preliminary release did not mention it. Source

Results and growth drivers

  • Fourth-quarter revenue rose 37%: Revenue was $11.3 million against $8.2 million a year earlier. Product revenue accounted for most of the increase. Source
  • Full-year revenue rose 20%: Full-year 2025 revenue was $33.6 million, up from $28.1 million in 2024. Product revenue was the main contributor to the increase. Source
  • Fourth-quarter net loss increased: Net loss was $12.5 million, or $0.28 per share, against $9.7 million, or $0.22 per share, in the fourth quarter of 2024. Source
  • Full-year net loss roughly unchanged: Full-year net loss was $47.1 million, or $1.05 per share, against $46.9 million, or $1.08 per share, in 2024. Source

Products, service and recurring revenue

  • Quarterly product revenue up 78%: Product revenue reached $9.3 million in the quarter. For the full year, product revenue was $23.4 million, up 25%. Source
  • Quarterly service revenue declined: Service revenue fell to $2.0 million. The company linked the decline to the volume of validation activities in each period. Source
  • Full-year service revenue rose 9%: Full-year service revenue was $10.2 million, compared with $9.3 million in 2024. Source
  • Recurring revenue grew double digits: Quarterly recurring revenue was $4.6 million, up 10%. Full-year recurring revenue was $17.8 million, up 15%. Source

“These milestones demonstrate the accelerating global adoption of the Growth Direct platform as our customers standardize on our technology across their manufacturing networks.”

Robert Spignesi, President and CEO

Customer orders and rollouts

  • Amgen order expanded global rollout: Amgen placed a significant multi-system order in the fourth quarter to expand its global Growth Direct rollout. Source
  • Amgen order called a record: Management called the Amgen order a record multi-system order. The January release had described a record order from an existing Top 20 customer. Source
  • Follow-on orders cited as support: The January release cited validation through multi-system and follow-on customer orders as support for the company's expected growth.

Costs, gross margin and expenses

  • Quarterly gross margin turned negative: Gross margin was negative 3% in the quarter, against positive 12% a year earlier. Adjusted for the write-off, it was 7%. Source
  • Inventory write-off excluded from adjusted margin: The company wrote off unusable inventory and recorded related warranty expense. Adjusted figures exclude these charges. Source
  • Full-year gross margin reached 3%: Full-year gross margin was 3%, against 0% in 2024. Adjusted for the write-off, full-year gross margin was 6%. Source
  • Quarterly cost of revenue rose: Total cost of revenue was $11.6 million in the quarter, up from $7.2 million a year earlier. Source
  • Full-year operating expenses declined: Operating expenses fell $1.4 million to $48.4 million. R&D fell 7% and sales and marketing fell 9%, while G&A rose 4%. Source
  • Quarterly operating expenses rose 6%: Quarterly operating expenses were $11.9 million, up 6%. R&D fell 5%, while sales and marketing and G&A each rose 11%. Source

“As we enter 2026, we believe the Company is well-positioned for continued growth supported by our proven track record of consistent execution”

Robert Spignesi, President and CEO

Cash, debt and capital

  • Cash near $39 million at year end: Cash, short-term investments and restricted cash were about $39.0 million at December 31, 2025. Source
  • Trinity Capital facility capacity remains: The company had $25.0 million of unused capacity under its debt facility with Trinity Capital at year end. Source
  • Cash and short-term investments declined: Cash and cash equivalents were $20.0 million and short-term investments were $18.3 million, against $16.9 million and $33.8 million in 2024. Source

Strategy and investor engagement

  • Four strategic priorities named: Management named accelerating Growth Direct placements, expanding gross margin, new product innovation and prudent cash management as strategic priorities. Source
  • MilliporeSigma partnership cited in January: The January release cited further advancing the MilliporeSigma partnership. The March release body names no MilliporeSigma update.
  • January conference presentation planned: Management had scheduled a presentation at the J.P. Morgan Healthcare Conference for January 15, 2026.

Coming up, as management said on 12 March 2026

  • Amgen Growth Direct Day in Q2: Amgen will sponsor a North American Growth Direct Day in the second quarter of 2026. Source

Figures management reported

FigureReported
Growth Direct systems placed, Q4 2025 Source16
Customer systems validated, Q4 2025 Source3
Growth Direct systems placed, 2025 Source28
Customer systems validated, 2025 Source18
Cumulative systems placed Source190
Cumulative systems validated Source155

Risks management discussed

  • Operational: The company recorded a write-off of unusable inventory and related warranty expense, which it excluded from its adjusted gross margin figures. Source
  • Demand: Service revenue moves with the volume of validation activities in each period, which the company cited as the reason for the quarterly decline. Source

Earlier plans management reported on

  • Ahead: The January release said fourth-quarter results exceeded the guidance raised in November.

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.